News

Cynbiose Respiratory joins the Atlanpole Biotherapies network

21 February 2018

CYNBIOSE RESPIRATORY, A NEW PRECLINICAL SERVICES COMPANY SPECIALISING IN RESPIRATORY DISEASES AND AEROSOL THERAPY, IS NOW A MEMBER OF ATLANPOLE BIOTHERAPIES.

Cynbiose Respiratory is a highly specialised clinical research company created on the basis of the know-how of its cofounders: the Cynbiose company, specialising in innovative preclinical models, and the Centre de Recherche Scientifique pour les Maladies Respiratoires (Centre for Scientific Research on Respiratory Diseases), INSERM UMR 1100, which contributes to the discovery and development of new treatments in this therapeutic field. The aim of Cynbiose Respiratory is to become the world leader in preclinical assessment of therapies for respiratory diseases and aerosol therapy.

Cynbiose Respiratory, which offers a range of innovative technologies and preclinical services for evaluation of the pharmacological profile and efficacy of drugs in the field of respiratory diseases and aerosol therapy, announced the start of its operations on 25 January 2018. In addition to preclinical evaluation, the company also provides a complete formulation service for bioproducts and small molecules, including signature of sprays and in vivo characterisation of candidate drugs and/or medical devices. Following its creation in 2017, the company is already working on the development of new prophylactic and therapeutic drugs for clients in both the academic and industrial sectors.

“With the creation of Cynbiose Respiratory, Cynbiose and the Centre for Scientific Research on Respiratory Diseases – INSERM UMR 1100 can call upon unique preclinical evaluation expertise in the field of respiratory diseases and aerosol therapy. As a founder of the company and an expert in the service industry, I am absolutely convinced of the pivotal role to be played and the benefits offered by hyper-specialised structures such as Cynbiose Respiratory, which will help speed up the development of therapeutic innovations”stated Hugues Contamin, co-founder, CEO of Cynbiose and President of Cynbiose Respiratory.